Results 171 to 180 of about 28,489 (306)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Theory and simulation of far field diffraction patterns in Talbot-based transient grating spectroscopy at X-ray free electron lasers. [PDF]

Sci Rep
Goloborodko A, Serrat C, Svetina C.
europepmc   +1 more source

Ceiling Effect Is Not the Only Effect [PDF]

Annals of Emergency Medicine, 2018
openaire   +2 more sources

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

MEK inhibition in adult patients with pilocytic astrocytomas. [PDF]

NPJ Precis Oncol
Rounis K, Delgado AF, Illies C, Shamikh A, Wangerid T, Jensdottir M, Bartek J, Persson O, Hietala MA, Friesland S, Carstens H, Stragliotto G.   +11 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Comment on 'Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoint Series' by Dajani et al.-The Authors' Reply. [PDF]

J Cachexia Sarcopenia Muscle
Arends J, Dajani O, Philips I, Skipworth RJE, Solheim TS, Laird BJA.   +5 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Is exercise an efficacious treatment for depression? A Comment upon recent negative findings

Frontiers in Psychiatry, 2013
Felipe Barreto Schuch, Marcelo Pio de Almeida Fleck   +1 more
doaj   +1 more source

Medical Photography for Scientific Publishing (MedPhotoPubl) in Rheumatology and Rehabilitation. [PDF]

J Korean Med Sci
Benlidayi IC.
europepmc   +1 more source